维普期刊资源整合服务平台（V6.5）

35篇 您的检索式：作者名="Reeder CB"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Cyclophosphamide,bortezomib and dexamethasone induction for newly diagnosed multiple myeloma:high response rates in a phaseⅡclinical trial显示文摘	Reeder CB Reece DE Kukreti V et a1	2009	Leukemia2009，23，7：	1
2	Once - versus twice - weekly bortezomib induction therapy with CyBorD in newly diag- nosed multiple myeloma 显示文摘	Reeder CB Reece DE Kukreti V	2010	Blood2010，115，16：	1
3	A phase Ⅱ trial of the oral roTOR inhibitor everolimus in relapsed aggressive lymphoma 显示文摘	Witzig TE Reeder CB LaPlant BR	2010	Leukemia2010，25，2：	1
4	A phaseⅡtrial of the oral m TOR inhibitor everolimus in relapsed aggressive lymphoma显示文摘	Witzig TE Reeder CB La Plant BR	2011	Leukemia2011，25，2：	1
5	Cyclophosphamide,bortezomib and dexamethasone induction for newly diagnosed multiple myeloma:high response rates in a phase Ⅱ clinical trial显示文摘	Reeder CB Reece DE Kukreti V	2009	Leukemia2009，23，7：	1
6	Cyclophosphamide bortezomib and dexamethasone induction for newly diag- nosed multiple myeloma:high response rates in a phase Ⅱ clinical trial显示文摘	Reeder CB Reece DE Kukreti V	2009	Leukemia2009，23，7：	1
7	Diagnosis and management of Waldenstrom macroglobulinemia:Mayo Stratification of macroglobulinemia and risk-adapted therapy(mSMART) guidelines显示文摘	Ansell SM Kyle RA Reeder CB		0，，09：	1
8	A phase Ⅱ trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma显示文摘	Witzig TE Reeder CB LaPlant BR		0，，：	1
9	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma显示文摘	Witzig TE Reeder CB LaPlant BR	2011	Leukaemia2011，25，：	1
10	Diagnosis and managenment of Wald -enstrom macroglobulinemia: Mayo stratification of macroglobuline -mia and risk-adapted therapy m(SMART)guidelines显示文摘	Ansell SM Kyle RA Reeder CB	2010	Mayo Clin Proc2010，85，9：	1
11	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma 显示文摘	Witzig TE Reeder CB LaPlant BR	2011	Leukemia2011，25，：	1
12	Diagnosis and management of Waldenstrom macroglobulinemia:Mayo stratification of macroglobu- linemia and risk-adapted therapy (mSMART)guidelines显示文摘	Ansell SM Kyle RA Reeder CB	2010	Mayo Clin Proc2010，85，9：	1
13	A phase Ⅱ trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma显示文摘	Witzig TE Reeder CB Laplant BR	2011	Leukemia2011，25，：	1
14	Cyclophosphamide, bort- ezomib and dexamethasone (CyBorD) induction for newly diag- nosed multiple myeloma: High response rates in a phase Ⅱ clinical trial显示文摘	Reeder CB Reece DE Kukreti V	2009	Leukemia2009，23，7：	1
15	Magnetic resonance imaging quantification ofliver iron显示文摘	Sirlin CB Reeder SB	2010	Magn Reson Imaging Clin N Am2010，18，3：	1
16	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/ lenalidomide/dexamethasone versus cyelophosphamide/ bortezomib/dexamethasone in newly diagnosed multiple myeloma显示文摘	Khan ML Reeder CB Kumar SK	2012	Br J Haematol2012，156，3：	1
17	Cyclophospha- mide,bortezomib and dexamethasone induction for newly diagnosed multiple myeioma: high response rates in a phase II clinical trial显示文摘	Reeder CB Reece DE Kukreti V	2009	Leukemia2009，23，7：	1
18	Cyclophosphamide,bortezo- mib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial显示文摘	Reeder CB Reece DE Kukreti V	2009	Leuke- mia2009，23，7：	1
19	Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma显示文摘	Reeder CB Reece DE Kukreti V	2010	Blood2010，115，16：	1
20	Diagnosis and managementof Waldenstrom macroglobulinemia : Mayo stratification of macro-globulinemia and risk - adapted therapy ( mSMART) guidelines显示文摘	Ansell SM Kyle RA Reeder CB	2010	Mayo Clin Proc2010，85，9：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示